Healthcare Services & Medtech.
A $109bn delivery market compounding at ~10.6% into the biggest institutional consolidation in Indian healthcare history: Temasek's Manipal filing a ~$1bn IPO at ~$10bn, Blackstone's Aster-Quality Care merger live, KKR taking HCG, and control deals printing at 31x EBITDA against global hospitals at 8-12x.
The scorecard
Indian healthcare is the PE sector par excellence: structural demand (health-insurance GWP compounding at 21%, medical tourism doubling to $16bn by 2030, PM-JAY now covering every citizen over 70), a fragmented supply side (the top-10 chains hold under 7% of private beds), and sponsors with control. The 2024-26 wave made it institutional: Temasek majority in Manipal, Blackstone's merged Aster-Quality Care at 10,600+ beds, KKR in oncology (HCG), ADIA in medtech (Meril at $6.6bn). The tension is arithmetic: buying beds now costs ₹4.3 cr each (Sahyadri at 31x EBITDA) versus ₹1.1-2.9 cr to build, listed comps trade at 36-40x against global hospitals at 8-12x, and ~34,000 new beds by FY29 will test occupancy just as ~$2bn of IPO paper (Manipal, Paras) hits the market. Demand is real; the cycle question is entirely about the price of it.
Insurance GWP at 20.9% CAGR (GST scrapped on retail health), medical tourism $8.7bn → $16.2bn by 2030, PM-JAY extended to all 70+ citizens.
Top-10 chains hold <7% of ~1.1M private beds: the long tail is the acquisition pipeline; mid-tier regional chains are the battleground (Cloudnine's 7-bidder process).
₹1.1-2.9 cr/bed to build; ₹4.3 cr/bed to buy (Sahyadri): acquisition premium now 2-3x replacement cost.
CGHS tariffs revised UP (Feb 2026: first in years); standing NPPA device caps and PM-JAY package rates below private tariffs remain the payor drag.
Control at 31x, listed at 36-40x, global at 8-12x; ~$2bn of IPO/OFS paper hitting 2026 tests absorption.
ARPOB +5-6%/yr and margin expansion (Fortis 20.4% → 22.8%) reward operators; multiple expansion is over: entry price is the whole trade now.
Scores are 0-100 favourability. Valuation Cycle at 38 is the read that matters: demand at 84 is already paid for at current multiples. Priors reflect the January 2026 read.
The numbers
$108.6bn (2024) at a 10.6% CAGR: inter-source variance is wide; TechSci delivery-only frame used
FY25-26 added as many beds as FY20-24 combined; ~34,000 more by FY29: 76% in metros
~$5bn+ record in 2025 (Sahyadri, HCG); hospitals take ~60% of every healthcare PE dollar
Demand · will supply get filled?
Demand here is a financing story: every point of insurance penetration converts cash patients into payor volume, and the payor pool is compounding at 21%.
Hospitals absorb 60 cents of every healthcare PE dollar, but single-specialty is the velocity story: IVF, oncology and eye care took 70%+ of that lane's money, the segment compounds at ~22%, and its IPO exits (Dr Agarwal's +20%, NephroPlus 14x subscribed) are already printing. Insurance penetration at 18%/14% is the decade of demand still unbought.
Output, order book & the global gap
Bed counts are capacity; admissions, surgeries and patient flows are output. The system-level throughput numbers, and the announced pipeline against them: decide whether the 34,000-bed build lands on demand or dilutes it.
The honest read: Indian healthcare output is compounding on every axis (admissions, transplants, robotic surgery, digital rails) and the cost arbitrage vs the world is real, but the market already pays 2.5-3x global multiples for it, the doctor ratio caps the tier-2 build, and Thailand still out-executes India on medical tourism per capita.
Competitive dashboard
The top six together hold well under 7% of India's ~1.1M private beds: the chart is the consolidators, not the market.
2023-26 institutional entries: every global sponsor of consequence now holds Indian healthcare control.
Capital · unit economics, valuation & deals
ARPOB, occupancy & multiples: The ARPOB ladder is the strategy map: premium-metro (Max) monetises beds at 1.7x the value chains, but the value end (Narayana, KIMS) compounds volume in uncontested geographies. Sector ARPOB grows 5-6%/yr: pricing power no other Indian consumer-facing sector reliably has.
Every global sponsor of consequence now holds Indian healthcare control: Temasek, Blackstone, KKR, EQT, ADIA, IHH. The Cloudnine bid sheet (seven names, several from our league table) is the clearest single snapshot of how crowded the entry gate has become.
The rotation is instructive: money left the richest ARPOB story (Max) for turnarounds (Fortis) and payors (Star Health). The market is pricing improvement, not premium: exactly the wrong tape to bring a ~$10bn IPO into, which is why Manipal's print matters beyond Manipal.
Private players & platforms
Where most of the value is still private: startup-, PE- and strategic-backed. Scale, ownership, and the last marker of value.
~$1.17bn IPO filed (H2 CY26); the sector's repricing event
NCLT merger completed Jun 2026: top-3 chain; Care Hospitals absorbed
Binding interest from KKR, TPG, Warburg, Advent, CVC, Permira, Kedaara: the sector's crowded-gate snapshot
Oncology control from CVC, closed Q3 CY25
Losing bidders: EQT, Blackstone, IHH, Temasek: the price of scarcity
ADIA 3% at $200M: Indian medtech's institutional mark
Startups & emerging players · the VC layer
Where venture capital enters the theme.
New hospitals reaching profitability within two months of launch; targeting company-wide profitability by FY26.
India-founded, largely US-revenue; ~$250M ARR, won't IPO until $400-500M ARR.
FY25 revenue ₹419cr, 95%+ diagnostics; capital aimed at smaller-city expansion.
40M+ users; profitable FY24 (₹170cr revenue, ₹15cr profit); now piloting a Novo Nordisk GLP-1 partnership.
~$36M 2024 revenue; round is mostly secondary, exiting early angels ahead of a future listing.
Headcount down 72% YoY even while expanding to UAE/US on ₹350cr revenue: a shrinking-team, mature business.
$193M debt raise (Sep 2025); still servicing Goldman Sachs/Kotak acquisition debt from the Thyrocare deal.
VC read: diagnostics and surgical-care chains (Redcliffe, Pristyn Care) are the crowded, capital-intensive segment now converging on unit profitability over growth multiples; PharmEasy's collapse is the sector's clearest cautionary tale on debt-funded roll-ups. White space is asset-light, AI-native, export-facing models: HealthifyMe's GLP-1 pivot and Innovaccer's US data-infrastructure play. E.
Public-market exposure index · rules-based, purity-weighted
A screened, exposure-weighted basket: each listed name weighted by its sector-exposure purity score (not naively equal-weighted), after liquidity and quality screens. Selection is rule-driven and set ex-ante.
Real point-to-point anchors: each name rebased to 100 at −3y; the −1y (173) and now (193) levels from its actual 1Y & 3Y returns, purity-weighted. Intra-period linear (daily shape/drawdowns need a price feed).
Rules-based: include a listed name if its healthcare-delivery purity score ≥ 20/100 AND it clears the eligibility screens. Weight by purity (exposure-weighted), single-name cap 25%, overflow redistributed pro-rata. Quarterly reconstitution. Selection is rule-driven, set ex-ante, not a curation of past winners.
- ✓ Liquidity & size: investable free-float, adequate ADTV
- ✓ Quality: positive profitability (excludes loss-makers)
- ✓ Purity: healthcare-delivery revenue / relevance score ≥ 20 of 100
Rules-eligible, pending verified data: Manipal (IPO H2 CY26: auto-eligible on listing), Aster DM Quality Care (merged entity seasoning), Paras Healthcare (DRHP filed), Yatharth, Jupiter Life Line. Purity scores are documented judgement tiers (Apollo's pharmacy/HealthCo dilutes; insurers and diagnostics are adjacent-purity legs). 1-yr figures sourced; 3-yr partly estimated (E): recompute from adjusted closes before external use.
Selection-bias caution: hospitals massively re-rated over the window (Fortis +239%, Max +207% over 3 yrs): past returns are upward-biased and NOT a forward estimate. The basket's insurer leg (Star, Niva) is the deliberate value/turnaround counterweight.
Research / informational only: not investment advice or a recommendation. Baskets are illustrative of the rules, not a managed product.
Externalities & policy footprint
The externalities and strategic stakes a government must price in.
Scenarios to 2030
26% capacity add in 2 years + PM-JAY payer-mix drag + ₹2bn of IPO paper → ARPOB stagnation; the multiple, not the business, breaks
ICRA Positive outlook holds; occupancy and ARPOB absorb the supply wave; Jefferies' Max 22% / Fortis 18% EBITDA CAGRs land
Insurance GWP compounds 21%, MVT doubles, tier-2 beds fill on schedule: the demand runway outruns every build plan
India's hospital multiples (25-35x EV/EBITDA) sit 2.5-3x above the US acute-care benchmark (HCA 10.9x), for businesses whose payer mix is drifting toward PM-JAY package rates and whose next 34,000 beds need specialists the 0.9-per-1,000 doctor ratio doesn't supply. The demand story is genuinely structural; the price already assumes it. Manipal's IPO is where assumption meets tape.
Financing · policy · catalysts
Exits run sponsor-to-sponsor (OTPP→Manipal, CVC→KKR) or reverse-merge into listcos (Quality Care→Aster): no continuation vehicle verified in Indian healthcare yet, unlike the PE mainstream. The capex cycle is self-funded at the top and QIP/IPO-funded below.
Sensitivities · what moves returns
Risks quantified, not just listed: the levers that swing the underwriting. Directional, illustrative.
Technology roadmap · what changes the game
Demand drivers
- ↑ Insurance formalisation: 21% GWP CAGR with GST removed: every new policy converts out-of-pocket demand into payor demand.
- ↑ Consolidation runway: top-10 chains under 7% of private beds; the fragmented tail is two decades of M&A pipeline.
- ↑ Pricing power: ARPOB compounds 5-6%/yr through every cycle: rare in Indian services.
- ↑ Medical tourism doubling to $16bn by 2030: export demand at domestic cost structures.
- ↑ Single-specialty velocity: focused formats (eye, IVF, dialysis, onco) scale faster, exit faster and now list successfully.
Risks
- ! Valuation cycle at full: 31x control deals and 36-40x listed comps against 8-12x global: the multiple has nowhere to expand.
- ! ~$2bn of IPO/OFS paper in 2026 (Manipal, Paras, sponsor sell-downs) tests a market already rotating out of premium names.
- ! Overbuild: 34,000 beds by FY29 vs ~10,000 in FY20-24; KIMS's margin dip previews the commissioning drag.
- ! Payor pressure both ways: PM-JAY package rates below tariffs, insurer-hospital cashless standoffs, NPPA cap precedent.
- ! Clinical talent scarcity in exactly the tier-2 geographies where 24% of new beds land.
What it means · by capital type
Entry price is the entire trade now: the sector rewards operators, not owners. The value pockets: mid-tier regional chains before the majors bid (Sahyadri's lesson), single-specialty platforms with IPO-proven exits, and diagnostics consolidation at sub-hospital multiples.
The Manipal print is your healthcare-book mark-to-market: Temasek, TPG and Novo are selling into it, and half our growth desk holds healthcare at 2024-25 entry multiples. If it clears $10bn, the vintage holds.
The rotation trade (long Fortis/Star, short Max) already paid 40+ points. Next: the IPO-supply overhang vs the CGHS-repricing tailwind, and Apollo's demerger as the value-unlock event the market hasn't fully priced.
PM-JAY's 70+ expansion buys volume at rates the private sector claims are below cost: the CGHS revision shows the fix works. Rate realism plus PLI's device-localisation gains (10% → 30%) is the durable version of health-cost sovereignty.
Data vintage July 2026. Anchored to 2025-2026 industry and official prints; figures across sources differ and are reconciled to the cited ranges. Sources: Bloomberg: Manipal $1bn IPO filing (Mar 2026)S · Bloomberg: Manipal-Sahyadri $700M (Jul 2025)S · CRISIL: private bed additions & capexS · CVC: HCG sale to KKRP · Aster DM: Quality Care mergerP · India Briefing: medical devices PLI progressS · Market backcasts, deal-value splits, bed-share chart: GW estimatesE
Data confidence. High on listed-operator results, CRISIL/ICRA bed programmes and named deals (P/S); medium on market-size series (2x inter-source variance, frame named) and annual PE/VC splits (derived from cumulative EY-IVCA data, directional). 'Apax-iD' could not be verified and is excluded.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
The sector, each cycle.
Healthcare Services & Medtech refreshed every cycle, with the scorecard, dashboard, and capital read. More sectors rolling out.
← All sectors